Get started
Author

Liansheng Huang

Observed names: LIANSHENG HUANG, Lian-Sheng Huang, Lian-sheng Huang
ORCID: 0009-0008-7866-5420
Observed ORCID: 0009-0008-7866-5420
OpenAlex ID: A5113748806
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
2014 · Xin He, Zhigang Chen, et al. · BMC Cancer · 148
PDF
CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2024 · Yang Xu, Xuzhao Zhang, et al. · Cancer Immunology Research · 10
Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.
2019 · Tong Chen, Yan Yuan, et al. · Journal of Clinical Oncology · 7
Peripheral T-cell lymphoma with hypercalcemic crisis as a primary symptom accompanied by polymyositis: A case report and review of the literature
2014 · LUYIN DING, XIBIN XIAO, et al. · Oncology Letters · 7
PDF
Myelofibrosis predicts deep molecular response 4.5 in chronic myeloid leukaemia patients initially treated with imatinib: An extensive, multicenter and retrospective study to develop a prognostic model
2024 · Tian Zeng, Xiudi Yang, et al. · Clinical and Translational Medicine · 4
PDF
Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome
2012 · Xiao-Hua Xu, Lian-Sheng Huang, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
[Following-up of nosocomial lower respiratory infection in patients with hematological malignancy after chemotherapy].
2008 · Qun Lu, Lian-sheng Huang, et al. · PubMed · 4
Dominant negative PD1 armored CART cells to induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.
2020 · Chengfei Pu, Liansheng Huang, et al. · Journal of Clinical Oncology · 3
[The clinical significance of hematological damage in systemic lupus erythematosus and related antibodies].
2006 · Xiao-ying Zhao, Ping Zhang, et al. · PubMed · 2
[Application of bone marrow biopsy imprint in evaluating cellularity].
2006 · Xing-guo Lu, Lian-sheng Huang, et al. · PubMed · 1
Detection and Clinical Significance of Thrombomodulin in Both Plasma and Tissue Extracts of Cancer Patients.
2004 · Xiaohua Xu, Liansheng Huang, et al. · Blood · 1
Detection and clinical significance of thrombomodulin in both plasma and tissue extracts of cancer patients
2004 · Xiao-hua Xu, Xing-guo Lu, et al. · Chinese Journal of Cancer Research · 1
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Data from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Abstract LB-379: Dominant negative PD1 armored CAR-T cells induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients
2020 · Yan Yuan, Liansheng Huang, et al. · Cancer Research
[Evaluation of biochemical metabolites by 31P MR spectroscopy in leukemic infiltration of liver].
2010 · Jian-zhong Sun, Zhi-kang Wang, et al. · PubMed
Cytomegalovirus interstitial pneumonitis following allogeneic peripheral blood stem cell transplantation
2005 · Xiao-hua Xu, Lian-sheng Huang, et al. · Chinese Journal of Cancer Research
Works count: 29
Citation count: 192
H-index: 4
I10-index: 2
Year
Topic
Type